J&J Enters LAA Closure Market In Earnest With Coherex Buy
This article was originally published in The Gray Sheet
J&J's Biosense Webster heart-rhythm device unit has acquired privately held partner Coherex Medical, solidifying its stake in the left atrial appendage closure market that Boston Scientific currently leads.
You may also be interested in...
As first-to-market in the US with a transcatheter left atrial appendage closure device, Boston Scientific has blazed a regulatory and reimbursement trail for other companies in this space and opened up a potentially billion-dollar-plus market. In this second part of our two-part series on LAAC devices, Medtech Insight reports on other companies with current and emerging LAAC devices and looks at how close they are to bringing their technology to the US market.
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.